摘要
T Objective： To evaluate the therapeutic efficacy and side effects of oral Fructus bruceae oil combined with radiotherapy in the treatment of esophageal cancer. Methods： A total of 80 patients with esophageal cancer were equally and randomly divided into two groups. The patients in Group A were treated with radiotherapy （60-65 Gy, 6-7 weeks） and oral Fructus bruceae oil （20 mL, 3 times per day for 12 weeks）, while the patients in Group B were treated with radiotherapy alone. The short-term effect was evaluated by Response Evaluation Criteria in Solid Tumors （RECIST） and quality of life （QOL） was evaluated by the Kamofsky scoring （KFS）. The outcome measures included complete remission （CR） rate, partial remission （PR） rate, effective rate as CR＋PR, patients＇ QOL and adverse effects. Results： After 12-week treatment, the CR and CR＋PR were significantly higher in Group A than those in Group B （P〈0.05）. There was an improvement in esophageal obstruction of 67.5% and 60.0%, respectively, and in KFS of 84.6% and 43.9%, respectively, in Groups A and B. Conclusion： Oral medication with oral Fructus bruceae oil could effectively improve the efficacy of radiotherapy in esophageal cancer, including a reduction in esophageal obstruction, and also reduce the side effects of radiotherapy; thus it would be very promising for clinical application.
T Objective： To evaluate the therapeutic efficacy and side effects of oral Fructus bruceae oil combined with radiotherapy in the treatment of esophageal cancer. Methods： A total of 80 patients with esophageal cancer were equally and randomly divided into two groups. The patients in Group A were treated with radiotherapy （60-65 Gy, 6-7 weeks） and oral Fructus bruceae oil （20 mL, 3 times per day for 12 weeks）, while the patients in Group B were treated with radiotherapy alone. The short-term effect was evaluated by Response Evaluation Criteria in Solid Tumors （RECIST） and quality of life （QOL） was evaluated by the Kamofsky scoring （KFS）. The outcome measures included complete remission （CR） rate, partial remission （PR） rate, effective rate as CR＋PR, patients＇ QOL and adverse effects. Results： After 12-week treatment, the CR and CR＋PR were significantly higher in Group A than those in Group B （P〈0.05）. There was an improvement in esophageal obstruction of 67.5% and 60.0%, respectively, and in KFS of 84.6% and 43.9%, respectively, in Groups A and B. Conclusion： Oral medication with oral Fructus bruceae oil could effectively improve the efficacy of radiotherapy in esophageal cancer, including a reduction in esophageal obstruction, and also reduce the side effects of radiotherapy; thus it would be very promising for clinical application.
基金
Supported by the Science-and Technology Plan, Development and Support Projects of Zhengzhou City （No. 0910SGYS33377-1 ）
